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H uman organs and tissues differ inregard to their clinical and researchuses and the regulatory legislation
controlling their use. Organs such as livers
and hearts are usually taken from donors
who are brain-dead; in addition, kidneys can
also come from live volunteers. Organs
decay rapidly and need to be transplanted
quickly. Surgeons and coordination teams in
transplantation centres control the procure-
ment, while dedicated national and interna-
tional organisations facilitate their
allocation.
Human tissues such as bone, skin and
heart valves are usually removed from
cadavers in hospitals, morgues or even
funeral homes and, unlike organs, can be
stored—sometimes for years—in tissue
banks. These tissues can be used in numer-
ous recipients as and when they are needed.
In the early days of human tissue banking,
not-for-profit banks, mostly located in
hospitals, dominated the field. The tissues
they stored—heart valves and skin, for
example—saved many lives.
......................................................
“Human tissues for research
are said to be worth more than
diamonds, being valued at US
$500/g.”
......................................................
Since the 1980s, the demand for human
tissues has increased dramatically. The first
tissue in significant demand was human
bone for use in allografts in orthopaedic
surgery. In the 1990s, the emerging field of
regenerative medicine, which generates
human tissue-engineered products (hTEPs),
began to require access to human tissues.
Eventually, pharmaceutical companies
began using human tissue instead of animals
in the early stages of medical product test-
ing. Human tissues for research are said to
be worth more than diamonds, being valued
at US$500/g.
Inevitably, commercial tissue banks were
set up to capitalise on this demand, starting
in the USA. Most US tissue bank companies
obtain their material through Willed Body
Donation programs, run by the bank itself or
through offshoots. They are allowed to
charge processors and distributors “reason-
able fees” for the procurement of cadaver
tissue—harvesting, transportation, refrigera-
tion and so on—rather than charging money
for the donated tissue itself, as it is illegal in
most countries to buy and sell human organs
or tissues that are donated for free. Next,
tissue processors and distributors can also
charge “reasonable fees” for their contribu-
tions: processing, packaging, distribution,
marketing and so on. Unfortunately, the term
“reasonable fee” has never been defined and
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this loophole is now being exploited to turn
altruistic donations into profits. International
tissue brokers and stock market listed tissue
processors and distributors are emerging,
with far-reaching consequences for the allo-
cation of human tissues.
......................................................
“. . . the term “reasonable fee”
has never been defined and
this loophole is now being
exploited to turn altruistic
donations into profits”
......................................................
In contrast to the USA, Europe initially
adopted a more restrictive attitude. Most of
Europe’s tissue banking activity remains at
hospital tissue banks, while some specia-
lised activities, such as tissue engineering,
are outsourced to biotechnology companies.
This situation has created tension between
the altruistic principles of hospital tissue
banks and industry’s profit-oriented princi-
ples. Meanwhile, industry lobbying and the
political desire to promote the growth of
biotechnology markets and jobs have led to
increasingly business-oriented legislation
controlling human tissue handling in the EU.
This shift has now gone so far that in some
legislations, the risk arises that the interests
of industry could take precedence over the
interests of patients and research.
T he legal framework for tissue dona-tion, banking and usage in the EU iscomprised of three EC Directives: the
parent Directive 2004/23/EC, which
provides the framework legislation, and two
technical Directives, 2006/17/EC and 2006/
86/EC, which give detailed requirements. In
2008, the Advanced Therapy Medicinal
Product (ATMP) Regulation (EC) No 1394/
2007, which covers hTEPs among other
things, came into force. Because public
health matters fall under the competence of
the EU Member States, the Directorate
General Enterprise of the European Commis-
sion invoked the “common safety concerns
in public health” clause, which falls under
the auspices of the EC, to create a regulatory
environment that would facilitate a market
for hTEPs. Pharmaceutical industry stan-
dards, such as good manufacturing practice
(GMP) and marketing authorisation, were
imposed upon the predominantly hospital-
based human tissue transplantation field. In
addition, the legal concept of “Tissue Estab-
lishment” was introduced, which expands
on the conventional concept of a tissue
bank. Companies with an accreditation as a
Tissue Establishment would thereby obtain
direct access to human tissues and cells.
These regulations have established a crucial
legal difference between organs and tissues:
human tissues are legally tradable goods in
a global market.
This commercialisation of human tissues
raises several ethical and public health
issues. Although acknowledging the legiti-
macy of these concerns, the EC invoked the
principle of subsidiarity—whereby the EU
only takes action in areas, which fall within
its exclusive competence—to relegate ethical
and public health issues to the Member
States. The regulation of hTEPs prepared on
a non-routine basis and used within the
same EU Member State in a hospital under
the exclusive responsibility of a medical
practitioner (referred to as the “Hospital
Exemption” rule) was also delegated to
national-level actors. As a consequence,
some member states have, through national
legislation, shifted the focus of tissue bank-
ing from public-health-oriented public tissue
banks to profit-oriented companies. We will
explain here how this is taking place in
Belgium under the radar of public attention.
B elgium is considered to have one ofthe best healthcare systems in Europe.It is sponsored by the state and
provided by a mixture of state-owned and
non-profit hospitals. The costs for patients
are partially or fully covered by a health
insurance fund and the government sets
reimbursement prices. As mandated by the
EU, Belgium has tried to address some ethi-
cal and public health issues in its implemen-
tation of the EC’s Tissue and Cell Directives.
The “Act regarding the procurement and use
of human body material destined for human
medical applications or for scientific
research purposes” was adopted on 19
December 2008 and entered into force on 1
December 2009. It defines “human body
material” as “any biological body material,
including human tissues and cells, gametes,
embryos and foetuses, as well as substances
extracted there from, whatever the degree to
which they have been processed”. The law
also introduced four types of “Tissue Estab-
lishments”: Banks for Human Body Material,
Intermediate Structures, Production Estab-
lishments and Biobanks. These “Tissue
Establishments” need to be accredited and
their activities and goals must be approved
by an ethics committee.
According to the Act, human body mate-
rial can only be procured by medical doctors
in recognised hospitals and collected by a
Bank for Human Body Material, which must
be operated by a certified hospital. From
then on, the “human body material
manager”—a medical doctor affiliated to the
bank—is responsible for the use of the mate-
rial, including the allocation to a patient or
Tissue Establishment. Banks for Human
Body Material should be set up as not-for-
profit establishments. An Intermediate Struc-
ture is only entitled to process, preserve,
store and distribute human body material
for further use in collaboration with a Bank
for Human Body Material. Production Estab-
lishments can perform all operations, includ-
ing production of ATMPs, provided such use
is exclusively for autologous purposes.
Commercial companies can obtain Interme-
diate Structure and/or Production Establish-
ment licenses in Belgium. The import and
export of human body material are restricted
to Banks for Human Body Material and
Production Establishments. The exact role of
Biobanks still needs to be clarified, but basi-
cally they will collect, process, preserve,
store and distribute human body material
for scientific research only.
......................................................
“While human tissue itself
cannot have human dignity,
human dignity is nevertheless
concerned when human tissue
is involved”
......................................................
In summary, industry has gained access to
autologous starting materials, but access to
and the future use of allogeneic tissues and
cells is controlled by not-for-profit hospital-
operated Banks for Human Body Material. It
is forbidden to store human body material for
future autologous use, unless it can be used
to treat a realistically impending pathology, or
if the material is put at the disposal of the
entire community. The prices for human
tissue and cell “products” and for some
processes are fixed by Ministerial Decree.
These prices basically cover the costs of
processing and leave no room for unreason-
able profits, thereby inherently preserving the
not-for-profit character of these activities.
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The ATMP “Hospital Exemption” rule
mentioned above, that is the regime pertain-
ing to ATMPs prepared on a non-routine
basis and used in a hospital within the same
EU Member State under the exclusive
responsibility of a medical practitioner, is
not resolved yet and is the subject of fierce
debate. More than 20 “products” produced
by nine Belgian hospital Banks for Human
Body Material are in fact ATMPs—we refer
to them as “cloaked” ATMPs—whereas only
a handful of ATMPs are produced by three
Belgian companies. Only one of these
commercial ATMPs, ChondroCelect—autol-
ogous chondrocyte cultures for symptomatic
cartilage lesions in the knee—is actually on
the market. It is the only hTEP-ATMP that
has obtained centralised European Marketing
Authorisation since the implementation of
the ATMP Regulation in 2008.
......................................................
“Differences in consent to
tissue donation, such as
opting-in versus opting-out,
create opportunities for
exploitation by companies that
lack ethical responsibility”
......................................................
The hospital-based Banks for Human
Body Material were notified by the Belgian
Federal Agency for Medicines and Health
Products that their products would fall under
the definition of an ATMP and that the
administration of these products to patients,
as had previously occurred, would no longer
be allowed after 30 December 2012. Since
then, the status of these now “uncloaked”
ATMPs has been contentious and their future
remains uncertain. Some of the products,
such as keratinocytes for severely burnt
patients, have been applied to thousands of
patients since the 1980s, and none of the
numerous inspections over the years have
ever revealed significant quality or safety
issues. When looking at these developments,
three questions come to mind: how can
“products” that are produced and used in
non-profit hospitals, and which originate
from altruistic donations, become commer-
cial medicinal products? Does it make sense
to implement the Hospital Exemption rule if
that rule de facto caters for the majority of
products? And why are products that were
developed 25 years ago suddenly called
“advanced” or “innovative”?
S ome of the measures introduced byBelgian legislators to prevent excessesquickly turned out to be futile. By way
of example, a private umbilical cord blood
bank—such banks have been criticised for
nurturing false hopes among customers—
found a way to bypass Belgian law and
obtained a license to operate (http://www.
journalismfund.eu/workinggrant/interna-
tional-offensive-cord-blood-banking). At the
same time, industry has started lobbying
Belgian policymakers for better access to
tissue material. The Commission on Social
Affairs of the Belgian Senate set up a work-
ing group to evaluate the “opportunities
and challenges associated with innovative
therapies”. The working group invited the
three Belgian commercial Production Estab-
lishments involved in ATMP production,
several professional trade associations and
a few start-up companies to join its evalua-
tion. However, the nine accredited hospital
counterparts that are responsible for more
than 20 formerly cloaked ATMPs, and the
hospital Banks for Human Body Material,
which provide the starting materials for cell
and tissue-based therapies, were not
invited.
According to their 2013 report, the work-
ing group identified three tissue bank-related
issues that allegedly hamper the ability of
companies to develop and commercialise
innovative hTEP-ATMPs: an insufficient
number of accredited public Banks for
Human Body Material to ensure a sufficient
supply of starting materials and the import
and export of finished products; a lack of
encouragement for Banks for Human Body
Material to collaborate with companies that
produce hTEPs; and the production of hTEPs
must be performed in accordance with GMP
standards, which the working group found
to be inconsistent with the purpose of Banks
for Human Body Material. However, accord-
ing to an expert from the Belgian Ministry of
Public Health, it has not been proved that
Banks for Human Body Material are disin-
clined to provide human body material to
the tissue engineering industry [1]. Indeed,
had representatives of the Banks for Human
Body Material been invited to the meetings
of the working group, they would have
argued against all three findings.
Regarding the first issue, the allegedly
insufficient number of accredited public
Banks for Human Body Material, we refer to
the list of accredited Tissue Establishments
published by the Belgian authorities (http://
www.fagg-afmps.be/nl/binaries/Lijst%20ML
M%20141016_tcm290-28032.pdf; http://www.
fagg-afmps.be/fr/binaries/Liste%20MCH%
20141016_tcm291-28032.pdf). According to
this list (updated 16 October 2014), no less
than 67 accreditations were issued (one
accreditation for each tissue type), not
including banks for human reproductive
tissue. For a country of 11 million inhabit-
ants, this is one of the highest concentra-
tions of Banks for Human Body Material
among all EU Member States.
Regarding the working group’s second
finding, the supposed lack of encouragement
of the Banks for Human Body Material to
collaborate with companies, the authors
know of only three requests for collabora-
tion between a company and a Bank for
Human Body Material. One of them led to
the development of the previously
mentioned ATMP ChondroCelect. Another
request involves haematopoietic stem cells
and the collaboration is still ongoing. A third
public–private partnership involved keratino-
cytes and lasted for more than 10 years
before both partners cancelled it a decade
ago, owing to the introduction of business
practices that were not compatible with the
bank’s mission statement: sales representa-
tives had influenced physicians’ choices,
keratinocytes were offered to privately
insured patients in less regulated or emerg-
ing markets, and a patent was applied for to
cover the possible cosmetic use of human
keratinocyte products. Successful collabora-
tions between Intermediate Structures and
Banks for Human Body Material are
certainly possible and desirable, but in order
to achieve this goal, Banks for Human Body
Material should first of all be recognised as
full partners and stakeholders.
......................................................
“If Belgian citizens were to
suspect that donated tissues
become part and parcel of
profit-maximizing activities,
they might be more likely to
exercise their right to opt-out”
......................................................
What about the third claim that GMP
standards are inconsistent with the purpose
of Banks for Human Body Material? As a
matter of fact, GMP standards might not be
consistent with the tissue transplantation
field as a whole, but since they were
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imposed, hospital banks cannot ignore
them. Even though not taken into account
by EU policymakers [2], the main purpose
of public hospital banks has always been to
provide quality grafts for therapeutic use.
Belgian Banks for Human Body Material
have already invested heavily in clean room
facilities and are getting ready to produce
hTEPs in compliance with GMP require-
ments, even though there is no evidence that
these investments will actually result in any
significant improvement to the quality or
safety of their grafts.
......................................................
“There is a risk that the final
destination of the donated
human body material may
partly be determined by differ-
ences in financial compensa-
tion”
......................................................
The working group’s report led to the
submission, on 21 January 2014, of a bill to
amend the Act of 2008 on the procurement
and use of human body material [3]. This
bill, if enacted, would allow Production
Establishments to produce both autologous
and allogeneic human tissue and cell prod-
ucts. It would give industry access to autolo-
gous and allogeneic human body material
and would provide industry with full control
over its use, without the need to collaborate
with a Bank for Human Body Material.
Belgian policymakers will now need to
decide which entities will control the access
to and use of donated tissue material. The
problem, however, is that the current actors
in the field have, to greater or lesser extent,
conflicting interest. The interests of the
general public, hospitals and industry are
not always in line with each other.
A rticle 21 of the 1997 Council ofEurope Convention of Human Rightsand BioMedicine provides that it is
not permissible for the human body or its
parts as such to give rise to profits. This
principle is based on the need to protect
human dignity and to ensure that persons
can be the authors of their own lives. With
the advent of the biotechnological era,
human dignity has been attributed an addi-
tional function—“human dignity as a
constraint”—to prohibit practices because
they compromise the intrinsic worth of
persons and the integrity of the human
species. These include human reproductive
cloning, germ line intervention, creation of
human chimeras, prenatal sex selection, and
the commercialisation of the human body
and its parts as such [4]. It does not,
however, prevent specific commercial activi-
ties, such as the patenting of human body
material in isolated, purified or slightly
modified form.
Concerning post-mortem procurement of
human body material for medical applications
or for scientific research, the Act of 2008
extends the presumed consent regime that
governs cadaveric organ transplantation in
Belgium: first, from post-mortem removal of
organs to post-mortem removal of any biologi-
cal material that falls under the scope of this
Act, and secondly, an extension from post-
mortem removal for therapeutic purposes to
post-mortem removal for research purposes.
In other words, the Belgian law equates the
absence of any registered objection to post-
mortem removal of organs for transplantation
with the absence of any objection to post-
mortem removal of any body material for any
purpose. No efforts have been made to inform
the public of this new legal regime for the
post-mortem procurement of body material.
While human tissue itself cannot have human
dignity, human dignity is nevertheless
concerned when human tissue is involved.
For some stakeholders, this implies that
tissues originating from an altruistic donation
should not be transformed into commercial
products and should only be handled by non-
profit-making tissue banks. In reality, private
companies process or engineer donated
human tissues and cells into more valuable
medicinal products, which often requires
extensive research and investments, which, it
is argued, justifies the commercialisation of the
resulting products. This is a dilemma, since
hTEPs now consist of a non-commercialisable
part (human body material) and a commer-
cialisable part (technological processing). A
possible solution would be to allow the
commercialisation of human body material
by companies that act in good faith—reflected
in reasonable processing fees and approval
from an ethics committee—and that produce
beneficial therapeutic products.
P ublic health is not a key priority forprivate companies: their primary obli-gation is to maximise profits for their
shareholders and investors. For human
tissue products, this means that companies
need to get access to starting materials and
at low cost. Differences in consent to tissue
donation, such as opting in versus opting
out, create opportunities for exploitation by
companies that lack ethical responsibility.
Countries such as Belgium, which have an
“opt-out” rule or presumed consent regime,
are therefore interesting for brokers and
corporate actors to get access to human
tissue material for processing into highly
profitable products. In this way, the values
of solidarity and the common good that are
supposed to underlie presumed consent are
increasingly being eroded.
If everybody were charging “reasonable”
fees, there would not be significant price
variations for the same product. Instead, a
wide variation in prices exists, ranging from
hundreds to thousands of dollars for the same
product. In sports medicine, tendon and bone
allografts, for instance, fetch higher prices in
areas with a flourishing sports culture than
tendon and bone products for general ortho-
paedics. Average human cell and tissue
product prices are almost five times higher in
the USA than in Belgium [5]. The Belgian
reimbursement price for ChondroCelect is
almost ten times higher than for the conven-
tional non-ATMP analogues produced by
two Belgian hospital Banks for Human
Body Material. Due to the high costs of
ChondroCelect, reimbursement is now
restricted to patients younger than 50 years.
In addition, some companies in the tissue
engineering field cater to cosmetics rather
than medical products. A striking example is
the processing of human skin, the gold stan-
dard for the treatment of severe burns, into
cosmetic products without medical indica-
tion, such as penis widening or lip enhance-
ments, which fetch much higher prices than
analogues for burn treatments. US burn
centres were reportedly struggling to obtain
skin because local tissue banks are commit-
ting all their donated skin to firms that
market products for plastic and cosmetic
surgery [6].
Such practices give rise to further
questions. Tissue Establishments have a
responsibility towards donors and donor
families. In the USA, research has shown
that donors wish that their donations result
in products that meet medical needs or
support research or medical education [6].
Donors and their families also expect their
tissue to be treated with respect. However,
human body material is increasingly viewed
as a marketable commodity.
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If Belgian citizens were to suspect that
donated tissues become part and parcel of
profit-maximising activities, they might be
more likely to exercise their right to opt-out.
This would put Belgium’s successful opt-out
donation system for organs, tissues and cells
for transplantation in jeopardy because the
current opt-out registers do not allow a
person to differentiate between the use of
their organs and that of any other body
material. Even if people became aware of
the Act of 2008, their only choice is between
opting out of all types of donations, including
for non-commercial organ transplantation,
or opting out of none.
H ospital-based Tissue Establishmentsmust be prepared to deliver humantissue with the required level of
quality and safety, but also respect and
protect the freedom of choice, the rights and
health of the donors, and prioritise the
collection and use of human body material
according to therapeutic and scientific rele-
vance. In hematopoietic progenitor cell
(HPC) transplantation, international stan-
dards are being designed to protect donor
safety, to prevent unnecessary pressure on
the donor and to ensure an unbiased infor-
mation process. These standards could be
adapted to all types of healthy volunteer
donations. A failure to regulate will increase
the risk of unethical trade practices, which
are usually associated with significant risks
to donor and recipient safety and could
negatively impact established not-for-profit
therapeutic applications.
Finally, we suspect that the current
Belgian regulatory framework will give rise
to a competition between tissue banks and
companies for access to limited and precious
human cells and tissues. There is a risk that
the final destination of the donated human
body material may partly be determined by
differences in financial compensation.
The Belgian healthcare system has tradi-
tionally been patient driven and based on
the principles of human dignity, equity of
access, quality and solidarity. These princi-
ples are not compatible with uncontrolled
commercialisation of human tissues and
cells. As explained above, the Belgian Act of
2008 has resulted in a twofold extension of
the presumed consent from post-mortem
removal of organs to post-mortem removal
of any human body material and from post-
mortem removal for transplantation to post-
mortem removal for research purposes. In
addition, a new bill, which is currently
under consideration in the Belgian parlia-
ment to amend the Act of 2008, would hand
over a significant measure of control of the
tissue transplantation field to industry.
Belgian citizens are unaware of this.
Ideally, the procurement and allocation
of human tissues and cells should be
controlled and facilitated by (inter)national
non-profit organisations, comparable to
organ donation and transplantation founda-
tions such as Eurotransplant and Swiss
Transplant. An excessive commercialisation
of human body material could lead to a loss
of trust in the transplantation field and could
put at risk the successful “opting out” or
“presumed consent” donation systems in
some EU Member States. Policymakers seem
enamoured by the methods and rhetoric of
industry, leading them to neglect the inter-
ests of donors and their families and eroding
the public values underlying the healthcare
system.
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